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Abstract  25 
Triazoles are the mainstay treatment for aspergillosis, though resistance to these 26 
antifungal agents may be associated with treatment failure. Refractory infections often 27 
necessitates the switch to other antifungal agents, including amphotericin B (AMB), 28 
though these infections may not resolve. The aim of this present study was to 29 
investigate the effect of prior azole exposure to AMB sensitivity in Aspergillus fumigatus 30 
biofilms. We hypothesised that sequential antifungal therapy has the potential to impact 31 
adaptive resistance mechanisms. Antifungal sensitivity was determined for each isolate 32 
against amphotericin B ± voriconazole (VRZ) exposure by a broth microdilution method 33 
and a XTT metabolic assay.  To analyse the role of extracellular DNA (eDNA) and 34 
Hsp90 activation, sensitivity to AMB ± DNA digesting enzyme (DNase) and Hsp90 35 
inhibitor (geldanamycin [GDA]) was also tested. Finally, scanning electron microscope 36 
imaging was performed to assess phenotypic changes. Our in vitro data revealed that A. 37 
fumigatus sensitivity to AMB was decreased when it was tested in combination with VRZ. 38 
In addition, a 2- to 4-fold decreased sensitivity to AMB was recorded against VRZ 39 
exposed germlings compared to controls. It was also shown that depletion of eDNA by 40 
DNase treatment enhanced AMB activity against VRZ exposed cells by 8-fold, which 41 
visually could be explained by the destabilisation of the biofilm when examined 42 
microscopically. Pharmacological inhibition of Hsp90 by GDA significantly improved 43 
biofilm susceptibility to AMB 4- to 8-fold. In conclusion, A. fumigatus pre-exposure to 44 
VRZ drug concomitantly induces eDNA release and activates the stress response, which 45 
collectively confers AMB resistance in vitro.  46 
KEYWORDS: Aspergillus fumigatus, biofilm, azole, polyene, eDNA, Hsp90 47 
48 
  3 
Introduction 49 
Aspergillus fumigatus is the most common species associated with invasive aspergillosis 50 
(IA), an opportunistic infection associated with high morbidity and mortality. Triazoles 51 
such as voriconazole (VRZ) and posaconazole are the mainstay of oral therapy and 52 
prophylaxis of aspergillosis. These compounds are fungistatic, inhibiting the enzyme 53 
complexes involved in the production of ergosterol, a key molecule involved in cell 54 
membrane integrity. However, the emergence of acquired azole resistance mechanisms 55 
among A. fumigatus isolates, such as alterations in the Cyp51a locus, is increasingly 56 
common and associated with treatment failure, leading to mortality rates of >88% in 57 
Europe [1]. Amphotericin B (AMB) is an alternative therapeutic option for IA, such as in 58 
patients who cannot tolerate VRZ or those who fail to respond to azoles.  59 
 60 
AMB is a fungicidal compound that actively binds to ergosterol and directly disrupts 61 
membrane integrity. Polyene resistance has not been a major clinical problem to date. 62 
However, there have been an increasing number of reports of clinically significant AMB 63 
resistance in fungal pathogens. A meta-analysis by Sterling and Merz (1998) reported 64 
that 59% of AMB resistance was acquired during treatment, and 86% of these cases did 65 
not clear infection [2]. The mechanism of AMB resistance in A. fumigatus is not yet fully 66 
understood. Recent studies have reported that A. fumigatus has the capacity to form 67 
biofilms, and these display adaptive antifungal resistance mechanisms [3-5]. It has been 68 
shown that these mechanisms confer altered resistance phenotypes depending on the 69 
phase of biofilm growth. A mutation in the ergosterol biosynthesis pathway has been 70 
reported to cause azole resistance and consequently triggers cross-resistance to AMB in 71 
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Candida spp. [6].  Treating Candida isolates with sub-inhibitory levels of azoles was 72 
shown to increase tolerance to AMB  in vitro [7]. However, in A. fumigatus the number of 73 
azole resistance isolates with non-Cyp51a mutation has increased over past few years 74 
and the impact of azole resistance on susceptibility to AMB remains unclear [8].  75 
 76 
The potential mechanisms of AMB resistance include alteration of cell wall components 77 
and reduced binding of AMB to membrane sterols. Based on our previous studies on 78 
adaptive resistance mechanisms in A. fumigatus biofilms, we hypothesised that azole 79 
selection pressure activates heat shock proteins (HSP90) and induces extracellular DNA 80 
(eDNA) release in A. fumigatus biofilms, therefore affecting subsequent AMB sensitivity.  81 
 82 
83 
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Materials and methods 84 
Strains and media 85 
A. fumigatus Af293, and three clinical strains isolated from the Royal Hospital for Sick 86 
Children (Yorkhill Division, Glasgow) were used throughout this study. For conidial 87 
preparation isolates were propagated on Sabouraud dextrose agar for 72h and conidia 88 
harvested, quantified and standardised to 1 × 105 conidia/mL in MOPS buffered RPMI 89 
for all subsequent studies, as described elsewhere [3].  90 
 91 
Susceptibility testing 92 
Time kill study was performed on Af293 to investigate the kinetics of VRZ (Pfizer 93 
Pharmaceuticals, NY, USA) and AMB (Sigma Aldrich, UK) either alone or in combination 94 
(VRZ-AMB), against 8h grown biofilm (germlings) at 2 × MIC90 (1 mg/L) of this strain.  At 95 
selected time points (1, 4, 12 and 24h) the cells were washed and the proportion of 96 
metabolic reduction compared to unchallenged cells assessed by XTT (2,3-bis(2-97 
methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-caboxanilide) assay [9]. Eight 98 
replicates for each time point were performed on two separate occasions. 99 
 100 
To investigate the effect of sequential treatment, biofilms were first treated with VRZ, 101 
followed by AMB.  Briefly, the standardised conidial inoculum for each strain was 102 
dispensed into flat bottomed 96 well microtitre plates and incubated for 8h at 37oC. The 103 
biofilms were then washed and treated with VRZ at a sub-MIC50 concentration of 0.06 104 
mg/L for 16h.  Biofilms were then challenged with AMB serially double diluted across 105 
each adjacent well of the microtitre plate to produce a concentration range of 0 to 64 106 
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mg/L. Next, to investigate the effect of VRZ pre-treatment and the role of eDNA or 107 
HSP90 in AMB sensitivity, a DNA digesting enzyme DNAse (128 mg/L, [Sigma]) or 108 
HSP90 inhibitor geldanamycin (GDA [50 mg/L], Invivogen) was tested in combination 109 
with AMB against VRZ exposed germlings, as described elsewhere [4, 5]. Each 110 
challenged biofilm was incubated for 24h at 37oC. Following challenge the antifungal 111 
drugs were washed 3X in PBS and the MIC50 determined by XTT assay, as described 112 
above. 113 
  114 
Scanning electron microscopy  115 
For scanning electron microscopy (SEM), representative biofilms grown and treated on 116 
Thermanox coverslips were processed as previously described [4]. Briefly, VRZ pre-117 
treated and control biofilms grown on coverslips were left untreated or treated with AMB 118 
(1 mg/L) in the presence and absence of DNase (128 mg/L) or GDA (50 mg/L) for 24h. 119 
Following treatment biofilms were fixed in 2% paraformaldehyde, 2% glutaraldehyde, 120 
and 0.15% [w/v] alcian blue in 0.15 M sodium cacodylate (pH 7.4). The biofilms were 121 




Analysis of variance (ANOVA) and t tests were used to investigate independent sample 126 
data. Bonferroni's correction for multiple comparisons was applied to the data where 127 
appropriate. GraphPad Prism (version 4; GraphPad, La Jolla, CA) was used for 128 
production of the figures. P values of <0.05 were considered significant. 129 
130 
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Results 131 
Time-kill analysis of early phase biofilm (Af293 - 8 h germlings) challenged with VRZ and 132 
AMB, either alone or in combination, demonstrated that at after 1 h AMB was 133 
significantly more effective than VRZ (p<0.001), but thereafter there were no significant 134 
differences observed (Figure 1). When the efficacy of VRZ and AMB used alone was 135 
compared to the combination, diminished activity was observed for each antifungal at 1, 136 
4, 12 and 24 h of treatment, with combination therapy being less effective in all cases.   137 
 138 
To examine the underlying mechanism involved in resistance to antifungal combinations, 139 
we investigated eDNA release and activation of HSP90 using appropriate inhibitors. 140 
Assessment of AMB sensitivity against germlings (Af293 and three clinical isolates) 141 
displayed a significantly higher MIC50 (the concentration that inhibited 50% XTT 142 
metabolism) by 2- to 8-fold, with VRZ pre-treatment (PT) compared to untreated 143 
germlings (p<0.05) (Figure 2). When treating the VRZ exposed germlings with AMB in 144 
the presence of DNase the MIC50 was significantly reduced by 4- to 8-fold compared to 145 
absence of DNase. In addition, pharmacological compromise of HSP90 by GDA also 146 
showed a synergistic effect of enhancing AMB activity by 4- to 16-fold (Figure 2A).  147 
 148 
To further investigate the impact of VRZ pretreatment, the morphology of A. fumigatus 149 
biofilm was investigated using SEM imaging. Striking architectural changes of A. 150 
fumigatus biofilms were observed upon VRZ pretreatment at the sub-MIC concentration. 151 
Biofilm treated with VRZ displayed increased level of ECM (indicated by white arrow in 152 
Figure 2B), and hyphal production was observed. Treating VRZ exposed biofilms with 153 
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AMB alone resulted in minimal damage compared to unexposed controls, however, the 154 
addition of AMB with DNase or GDA caused more hyphal cell damage throughout the 155 
biofilm (indicated by arrow head in Figure 2B). Treating biofilm with DNase on its own 156 
display less ECM and disrupted biofilm architecture. The HSP90 inhibitor GDA on its 157 
own had less or no effect on biofilm morphology. Taken together, these results indicate 158 
that exposure of germlings to VRZ induces changes in morphology of A. fumigatus 159 
biofilms, which impacts AMB activity, depletion of eDNA and HSP90 inhibition enhancing 160 
the efficacy of AMB. 161 
 162 
163 
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Discussion  164 
In vitro the results of this study establish the adverse effect of VRZ exposure on 165 
subsequent AMB treatment in A. fumigatus. Resistance of A. fumigatus biofilms to 166 
antifungal drugs including the azoles is increasingly common, often requires surgical 167 
removal of the infected substrate. The mechanisms of antifungal resistance in fungal 168 
species are complex and some are shown to be adaptive responses. The mechanisms 169 
including mutation in CYP51A gene, efflux pump activity, HSP90 activated calcineurin 170 
signalling pathway and presence of eDNA have been  reported to be associated with 171 
antifungal resistance in A. fumigatus [3-5, 8]. Although, some of the reported 172 
mechanisms were induced and contributed to azole resistance, their role in cross-173 
resistance to other antifungal drugs remains unclear. In C. albicans, it was demonstrated 174 
that biofilms pretreated with fluconazole significantly decreases the efficacy of sequential 175 
caspofungin treatment, which was shown to be mediated by HSP90 and calcineurin 176 
signalling pathway [10].  Kelly and colleagues (1997) established that defective sterol 177 
Δ5,6 - desaturation causes fluconazole resistance in clinical isolates which results in 178 
reduced levels of ergosterol in the  cell membrane, which in turn causes cross-179 
resistance to AMB [6]. In this study, we have shown that azole selection pressure 180 
activates other resistance mechanisms such as HSP90 and eDNA in A. fumigatus which 181 
influences subsequent AMB treatment. 182 
 183 
Previous studies show that both VRZ and AMB exhibit their greatest activity against 184 
newly germinated conidia compared to multicellular hyphae [9]. However, AMB is 185 
generally more effective than VRZ against the fully formed hyphal populations, which 186 
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may be due to the fact that AMB does not require actively growing cells to elicit its action. 187 
This is clear from time kill studies showing that AMB displayed rapid and highly 188 
significant antifungal activity compared to VRZ after only 1 h (Figure 1). Nevertheless, 189 
increased resistance to all agents tested was observed in older hyphal populations 190 
which may be due in part to the presence of extrapolymeric material [11].  191 
 192 
Due to the resistance of older hyphal populations, we focussed on the early germinated 193 
hyphal phase of growth to determine how rapidly each drug elicits its action. The data 194 
indicated that, while AMB was significantly more active at 1 h, both drugs were highly 195 
effective with no significant differences between them at 4, 12 and 24 h. When both 196 
drugs were tested in combination, a significant reduction in activity compared to either 197 
drug alone was seen. This is in contrast to studies performed with planktonic cells, 198 
where Perkhofer et al (2007) investigated in vitro antifungal combinations, demonstrating 199 
both indifference and synergism with combinations of VRZ-AMB [12]. In an in vivo model 200 
of IA Kirkpatrick and colleagues (2006) reported that VRZ alone or in combination with 201 
AMB was most effective in reducing the mortality and fungal tissue burden, noting no 202 
antagonism between the drugs [13]. A second report concluded there was no significant 203 
difference between groups of guinea pigs receiving VRZ alone or VRZ-AMB, and activity 204 
was neither enhanced nor reduced with the combination of two antifungal agents [14].  205 
 206 
Secondly we have shown that pre-exposure of A. fumigatus germlings to sub-inhibitory 207 
concentration of VRZ increases tolerance to AMB by 2 to 4 fold.  This is similar to the 208 
findings by Vazquez and colleagues (2007) who demonstrated a pronounced increase in 209 
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resistance to AMB with overnight exposure to azoles in Candida spp. The kill rate of 210 
Candida by AMB has shown to be significantly reduced after pre-exposure to either 211 
fluconazole or itraconazole for 16h [7]. When it comes to the mechanism of resistance 212 
SEM images suggest that VRZ treatment increases ECM production (Figure 2B), which 213 
directly impacts the AMB binding with sterols. The molecular chaperone HSP90 214 
regulates azole resistance through different mechanisms including marked control over 215 
biofilm ECM production [4]. Pharmacological depletion of HSP90 significantly reduced 216 
AMB MIC in VRZ exposed cells, providing a compelling mechanism by which VRZ might 217 
confer AMB resistance. Recent studies established the presence of eDNA in fungal 218 
biofilms plays a role in biofilm stability and antifungal resistance [5, 15]. Stimulation of 219 
eDNA release by antifungals is not known to occur in fungal biofilms. However in 220 
bacterial biofilms low levels of β-lactam antibiotics induce eDNA release and biofilm 221 
formation. In this study, DNase was shown to enhance the efficacy of AMB following 222 
VRZ exposure suggesting that VRZ might also stimulate resistance by inducing eDNA 223 
release. 224 
 225 
In conclusion, our data signify that A. fumigatus grown in the presence of VRZ induces 226 
tolerance to AMB. Our in vitro data suggest that inappropriate use of azoles may cause 227 
sequential AMB treatment be counterproductive. Finally, the use of DNase or Hsp90 228 
inhibitor in combination with AMB appears promising to overcome the problem. 229 
 230 
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Figure Legends 287 
Figure 1. Pharmocodynamics of voriconazole, amphotericin B alone and in 288 
combination against A. fumigatus germinated conidia. Figure shows the time-kill 289 
kinetics of AMB (1 mg/L), VRZ (1 mg/L) either alone or in combination against Af293 290 
germinated conidia (8h). Results are the average of eight replicates carried out on two 291 
separate occasions and are expressed as the proportion of cellular viability determined 292 
by the XTT assay. Error bars represent the standard deviation of the means. Significant 293 
differences are represented by an asterix (* p<0.001). 294 
 295 
Figure 2. Pre exposure to voriconazole stimulates AMB tolerance. A. fumigatus 296 
germlings was grown in RPMI at 37oC and pre-treated with VRZ (+VRZ PT) or vehicle (-297 
VRZ PT) for up to 24h. (A) MIC50 of AMB ± DNase (128 mg/L) and AMB ± GDA (50 298 
mg/L) was determined by broth micro dilution method for each isolates. Bar graph 299 
shows the mean MIC50 value of all tested isolates (Af293  and three clinical isolates). 300 
Error bars represent the standard deviation of the means. Significant differences are 301 
represented by an asterix (*p<0.05). (B) VRZ pre-treated and control biofilms grown on 302 
coverslips were left untreated or treated with AMB ± DNase and AMB ± GDA for 24h. 303 
Following drug exposure, biofilms were fixed and imaged by SEM. Representative 304 
biofilm from each group is shown in figure. The white arrow indicates biofilm matrix and 305 
arrowhead indicates burst and broken hyphae in the biofilms. 306 
